CTI(SZ:300012) Ge Long Hui A P P·2026-01-21 08:58Core Viewpoint - Huace Testing's Q4 2025 performance forecast exceeds expectations, driven by both organic growth and external acquisitions [1] Financial Performance - The company's net profit attributable to shareholders for the full year 2025 is projected to be between 1.013 billion and 1.021 billion yuan, representing a year-on-year increase of 10-11% [1] - The net profit excluding non-recurring items is expected to be between 947 million and 956 million yuan, also reflecting a year-on-year growth of 10-11% [1] Business Drivers - The better-than-expected performance is attributed mainly to strong results in the food sector and recovery in the pharmaceutical business, leading to higher-than-expected organic growth [1] - The ongoing internationalization strategy is expected to continue generating additional growth in 2026 [1] Strategic Initiatives - The company aims to enhance its lean laboratory coverage and leverage it to empower acquired companies [1] - Active exploration of AI technology to address industry pain points is underway, with the potential for AI-driven laboratories to lead industry transformation [1] Investment Outlook - The company maintains a "outperform industry" rating with a target price of 17.15 yuan, corresponding to price-to-earnings ratios of 24.9 and 21.4 for 2026 and 2027, respectively, indicating a potential upside of 12.8% from the current stock price [1]